WO2026061466 - FUSED TETRACYCLIC COMPOUNDS AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/061466
Publication Date
26.03.2026
International Application No.
PCT/CN2025/122430
International Filing Date
19.09.2025
Title **
[English]
FUSED TETRACYCLIC COMPOUNDS AND USE THEREOF
[French]
COMPOSÉS TÉTRACYCLIQUES FUSIONNÉS ET LEUR UTILISATION
Applicants **
JACOBIO PHARMACEUTICALS CO., LTD.
Inventors
LI, Haijun
CHEN, Mingming
WANG, Peng
WANG, Yanping
Priority Data
PCT/CN2024/119958
20.09.2024
CN
PCT/CN2024/138317
11.12.2024
CN
PCT/CN2025/070732
06.01.2025
CN
PCT/CN2025/074247
23.01.2025
CN
PCT/CN2025/102375
20.06.2025
CN
PCT/CN2025/107719
09.07.2025
CN
PCT/CN2025/111381
30.07.2025
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2801 | |
| EPO | Filing, Examination, Granting | 20827 | |
| Japan | Filing, Examination, Granting | 2646 | |
| South Korea | Filing, Examination, Granting | 3396 | |
| USA | Filing, Examination, Granting | 9340 |
Total:
39,010
Contact Us
Abstract[English]
The invention relates to compounds of formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof or a PROTAC molecule thereof that selectively inhibit the activity of K-Ras G12D protein, compositions comprising the same, the methods of using the same and related intermediates.[French]
L'invention concerne des composés de formule (I), un stéréoisomère de ceux-ci, un sel pharmaceutiquement acceptable de ceux-ci, un sel pharmaceutiquement acceptable du stéréoisomère de ceux-ci, un promédicament de ceux-ci, une molécule deutérée de ceux-ci ou une molécule PROTAC de ceux-ci, lesquels inhibent sélectivement l'activité de la protéine K-Ras G12D, des compositions les comprenant, leurs procédés d'utilisation et des intermédiaires associés.